Jomed Goes Public, At Last
Two years ago, Jomed NV, one of the most promising of the small cardiovascular device companies, saw itself following in the footsteps of then-rising star, Arterial Vascular Engineering Inc. By the time Jomed was planning its IPO in the middle of last year, the market for medical device IPOs had cooled substantially from its peak three years earlier, as wary investors all but turned their backs on new device plays. That Jomed finally did go public last month and its stock has continued to do well, albeit over a short period of time, speaks to both the promise of the company and, officials throughout the medical device industry hope, a new appetite for medical technology issues.
You may also be interested in...
For Volcano Therapeutics, the addition of Jomed's IVUS business is both an addition to and diversification beyond its current play in thermography as a diagnostic tool to detect vulnerable plaque.
Abbott Laboratories broke into the spinal market with its acquisition of Spinal Concepts, and expanded its interventional cardiology product line by acquiring Jomed's coronary and peripheral interventional product lines. Both deals reflect the increasing convergence in medical devices of drug and device therapies.
By all accounts, the one piece missing from the puzzle for Jomed NV, the small European supplier making waves in the highly competitive field of interventional cardiology, has been a US presence. Thus, most industry observers saw the value in Jomed's merger with Endosonics as providing it with a US sales and marketing infrastructure.